The Canadian Agency for Drugs and Technologies in Health (CADTH) has opened consultations and is inviting feedback on the following three proposals:
- Does the agency need to improve the common drug review (CDR) processes for establishing reimbursement criteria? This is in response to jurisdictions requesting more detail and consistency on the Canadian Drug Expert Committee (CDEC) initiation, renewal and discontinuation of recommendations. The consultation details can be found here.
- Publication of draft CDR review reports: This involves increasing transparency by making manufacturer comments and CADTH responses publicly available and moving the redaction process to after the CADTH response has been finalised. The consultation details can be found here.
- How to respond to situations where firms decline to put their drugs forward for assessment: In response to instances where manufacturers have declined to file reimbursement submissions for eligible products, CADTH is proposing a formalised public communication process for such instances. The consultation details can be found here.
There is a standardised feedback template as well as advice on its presentation and formatting that can be found here.
The consultation closes at 17:00 ET on 10 September 2018.